Novo Nordisk (A): Global Coordination Custom Case Solution & Analysis

Evidence Brief: Novo Nordisk Global Coordination

1. Financial Metrics

Market Leadership: Novo Nordisk maintains approximately 50 percent of the global insulin market share by volume.
Revenue Concentration: Sales are heavily weighted toward North America and Europe, though emerging markets show higher growth rates in diabetes prevalence.
R and D Investment: The company allocates approximately 15 percent of annual sales to research and development, focusing on long-acting insulins and GLP-1 therapies.
Operating Margins: Historical margins exceed 30 percent, though pricing pressure from United States payers and European cost-containment measures threatens these levels.

2. Operational Facts

Geographic Footprint: Operations span 70 countries with products marketed in approximately 180 territories.
Organizational Structure: Transitioning from a decentralized model where regional affiliates held significant autonomy to a more centralized Global Marketing function.
Product Lifecycle: Launch cycles for primary products like Victoza require simultaneous coordination across diverse regulatory environments.
Headcount: Total global workforce exceeds 29000 employees, with a significant portion dedicated to local sales and medical affairs.

3. Stakeholder Positions

Lars Rebien Sorensen (CEO): Advocates for a unified global approach to maintain brand consistency and operational efficiency.
Jakob Riis (SVP International Marketing): Tasked with bridging the gap between headquarters and regional affiliates; faces resistance from local managers used to autonomy.
Regional Managers: Argue that local market nuances, such as reimbursement policies and cultural attitudes toward diabetes, require local control over marketing spend.
Global Product Teams: New cross-functional units designed to integrate R and D, marketing, and production decisions.

4. Information Gaps

Specific Affiliate P and L: The case does not provide a granular breakdown of profitability by specific country-level affiliates.
Competitor Response Times: Data on how quickly Sanofi or Eli Lilly respond to Novo Nordisk global launches is limited.
Internal Cost of Coordination: The direct administrative cost of the new Global Marketing structure is not quantified.

Strategic Analysis

1. Core Strategic Question

The central dilemma is how Novo Nordisk can transition from a collection of autonomous local entities into a coordinated global enterprise without stifling the local agility required to navigate diverse healthcare reimbursement systems.

2. Structural Analysis

Integration-Responsiveness Grid: The diabetes care market has shifted. High integration is now required due to global clinical standards and payer demands for consistent data. However, high responsiveness remains necessary because of localized pricing and distribution.
Value Chain Analysis: Primary value is created in R and D and Manufacturing (centralized), while marketing and sales (decentralized) have historically captured that value. The current friction exists because the centralized R and D output requires a more unified global marketing narrative to justify premium pricing.
Porter Five Forces: Buyer power is the dominant force. Large pharmacy benefit managers and national health systems demand uniform clinical evidence, making the old model of varied local messaging obsolete.

3. Strategic Options

Option	Rationale	Trade-offs	Resource Requirements
Hard Centralization	Eliminate affiliate marketing roles; run all campaigns from Copenhagen.	Maximum efficiency but risks alienating local medical communities.	Significant HQ headcount expansion.
The Global Product Team (GPT) Matrix	Empower GPTs to set global strategy while affiliates execute within strict guardrails.	Balances global scale with local insights but increases meeting frequency and decision latency.	New IT systems for global collaboration.
Center of Excellence Model	Affiliates retain power but must purchase services from global centers of excellence.	Maintains local P and L ownership but risks internal fragmentation.	Internal transfer pricing mechanisms.

4. Preliminary Recommendation

Novo Nordisk should adopt the GPT Matrix model. This approach recognizes that while the core clinical data for a drug is global, the path to reimbursement is local. By giving GPTs authority over the core brand message and clinical data sets, the company ensures consistency. By leaving tactical execution and local pricing negotiations to the affiliates, it maintains market access speed.

Implementation Roadmap

1. Critical Path

Phase 1 (Months 1-3): Define the decision rights for Global Product Teams using a RACI matrix. Explicitly state that HQ owns the brand narrative and clinical evidence, while affiliates own the local stakeholder relationships.
Phase 2 (Months 4-6): Align incentive structures. Move affiliate manager bonuses from purely local sales targets to a blend of local performance and global product launch milestones.
Phase 3 (Months 7-12): Roll out the unified digital marketing platform to ensure all affiliates use approved, consistent assets.

2. Key Constraints

Cultural Resistance: Veteran affiliate managers in large markets like the United States or Germany may view centralization as a loss of status, leading to passive-aggressive compliance.
Regulatory Variance: The speed of the global rollout is constrained by the slowest national regulator, which can create inventory bottlenecks if not managed centrally.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of local disengagement, the implementation will include a shadow period. For the first two product launches under the new system, affiliates will participate in the GPTs as consultants before the full transfer of strategic authority occurs. This allows for the refinement of coordination protocols before they are codified into corporate policy.

Executive Review and BLUF

1. BLUF

Novo Nordisk must centralize strategic brand management to combat increasing payer power and biosimilar competition. The historical model of affiliate autonomy is no longer viable in a market where clinical evidence and pricing are scrutinized globally. The company should implement a matrix structure where Global Product Teams dictate the strategic core, while affiliates manage local execution. This shift is the only way to ensure the successful global launch of complex therapies like Victoza and Tresiba. Failure to coordinate will result in fragmented messaging and eroded margins as payers exploit inconsistencies across markets.

2. Dangerous Assumption

The analysis assumes that local affiliates possess the necessary skill sets to pivot from strategic decision-makers to execution specialists. If the talent at the local level is optimized for autonomy, the new centralized structure may face a significant competency gap during execution.

3. Unaddressed Risks

Payer Arbitrage: Even with a coordinated strategy, national health systems may use the centralized pricing data to demand the lowest global price, leading to a race to the bottom for margins. (Probability: High; Consequence: Severe).
Operational Gridlock: The matrix structure may lead to an over-reliance on consensus, slowing down response times to local competitor moves. (Probability: Medium; Consequence: Moderate).

4. Unconsidered Alternative

The team did not fully evaluate a geographic consolidation strategy. Instead of coordinating 70 individual countries, Novo Nordisk could cluster affiliates into five regional hubs with full P and L authority. This would provide more scale than the current local model while remaining more agile than a fully centralized Copenhagen-led structure.